Oncodesign provides information related to the June 30, 2022 general meeting of shareholders

Dijon, France, June 13, 2022– (Business Wire) – Regulatory News:

ONCODESIGN (FR0011766229 – ALONC) (Paris: ALONC), a biopharmaceutical group specializing in precision medicine, announces the availability of preparatory documents for the June 30, 2022 joint general meeting.

In addition, the company informs its shareholders that Its general session will be held Thursday, June 30, 2022DIJON at 20 Rue Jean Mazen at 9:30 a.m. (and not as previously announced on June 29, 2022).

Documents relating to this General Meeting have been made available to shareholders and can be consulted on the Investors / Documentation / General Meetings section on the Uncodesign website: https://www.oncodesign.com/fr/documentation/assemblees- generals / general- assembly- 2022

It is also possible to consult the documentation at the company’s registered office at 18 rue Jean Mazen in DIJON – 21000. Each shareholder may request to send him a copy of these documents.

About Oncodesign: www.oncodesign.com

Oncodesign is a biopharmaceutical company founded in 1995 by its current CEO and a majority of shareholders, specializing in precision medicine. It has been listed on the Euronext Growth Market since April 2014. The goal is to find effective therapies to fight cancer and other diseases. Without therapeutic solution. . Based on a unique technological platform combining artificial intelligence, pharmaceutical chemistry, pharmacology, regulatory bioanalysis and advanced medical technology imaging, Uncodesine is a new selection supported by unique experience gained with over 1,000 customers, including the world’s largest pharmaceutical company. Therapeutic targets, design and development of potential pre-clinical candidates up to the clinical phase stage. Oncodesign has configured its firm to license its customers innovative services and proprietary molecules. With an estimated market of more than 65 65 billion by 2027 and about 25% of R&D investment in the pharmaceutical industry, kinase inhibitors have been applied to the molecule, oncode sign technology has already been able to target several molecules of interest with high therapeutic potential. To sign partnerships with oncology and external oncology, and international pharmaceutical groups. Located in Disney, France, centered around university and hospital centers and within the Paris-Sacle cluster, Oncodesign has 3 business units (BU): Services, Biotech, Artificial Intelligence and affiliates in Canada and the United States.

Future plans

This document contains insightful statements and estimates about the financial situation, results of operations, strategies, plans and future performance of the company and the market in which it operates. Some of these statements, predictions and conjectures may be recognized by the use of words such as, without limitation, “belief”, “expected”, “expectation”, “expectation”, “project”, “plan”, “inquiry”, “conjecture”. , “Maybe”, “wants” and “will” and other similar expressions. They include things that are not historically true. Such statements, predictions and assumptions are based on various assumptions and assessments of known and unknown risks, uncertainties and other factors, which were considered reasonable at the time of making but may not be proven accurate. Actual events are difficult to predict and can depend on factors beyond the control of the company Accordingly, actual results, financial condition, performance or achievement of the company, or industry results, may differ materially from any future results, performance or achievement which is not represented in the light of such uncertainties expressed or implied by such statements, predictions and assumptions. As the justification or justification of these far-sighted statements, predictions and conjectures. In addition, farsighted statements, forecasts and estimates speak only as to the date of publication of this document. The Company denies any obligation to update any such prudent statement, forecast or assumption that reflects any change in the Company’s expectations, or any change in the event, situation or circumstance on the basis of which such statement, forecast or assumption is made. , Except as required by French law.

See the source version at businesswire.com: https://www.businesswire.com/news/home/20220613005671/en/

Introduction

Oncodesign
Philip Gain
Chairman and CEO
E.g. : +33 (0) 380 788 260
investors@oncodesign.com

Newcap
Investor Relations
Mathild Bohin
E.g. : +33 (0) 144 719 495
oncodesign@newcap.eu

Newcap
Media Relations Arthur Rouille
E.g. : +33 (0) 144 710 015
oncodesign@newcap.eu

Leave a Comment